Sources of slides and information. roi/main.html. CME slide kit : Rush University Medical Center
|
|
- Verity Walker
- 5 years ago
- Views:
Transcription
1
2
3 Sources of slides and information com/hiv conference/c roi/main.html CME slide kit : Rush University Medical Center
4 Modified from Rick Elion, MD Associate Professor, George Washington University School of Medicine, Washington, DC
5 1,378 Patients at 10 US Clinics followed From Median Peak CD4 was 900 progressively higher for 800 specific CD4 strata (p<0.001) 700 Multivariate analysis: Increased mortality with CD4 < (HR=4.6) and CD (HR=2.6) compared to 200 cells/mm Lower BL CD4 at initiation also 300 associated with increased risk 200 of death from non-aids-related causes Median CD4+ cell count versus years after HAART start by baseline CD4+ category < HAART start year 2 year 4 year 6 Palella F, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 983.
6 Proportion of CD4 350 cells/mm 3 at first presentation has increased from 34% to 47% (P 0.01) 01) Median CD4 on presentation has increased from 234 to 327 cells/mm 3 (P<0.01) NA-ACCORD ACCORD analysis (N=35,009) Still <50% of patients in the West Presented Late to Care Althoff K, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 982.
7 Washington DC has an estimated HIV seroprevalence 400 of 3% DOH expanded HIV testing to be included in 300 routine care with improved 250 clinical linkages From 2004 to 2006, HIV tests 200 increased from 19,000 to , Among newly diagnosed, median CD4 50 count increased 57% 0 ount at Presentati ion an CD4 C Medi CD4 at Initial Presentation HIV testing in routine care p< Year of Diagnosis i Castel A, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 34.
8 Multicenter t cohort study Odd R ti f C iti I i t b CD4 N di (CHARTER) of 1526 pts evaluating 40% had HAND (HIVassociated Neurocognitive Disorders 70% were asymptomatic only a few (n=27) had frank dementia Odd ds Ratio Odds Ratio for Cognitive Impairment by CD4 Nadir < CD4 Nadir High CD4 350 associated with a lower risk of HAND (multivariate analysis) Ellis R, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 429.
9 Period of declining new HIV diagnoses in BC coincident with increased HIV testing rates, increased uptake of antiretroviral therapy, and decrease in community viral load ( ) Decline in new HIV diagnoses despite increases in syphilis, gonorrhea, chlamydia Patients (n) 12,000 10, New HIV+ diagnoses (all) Censored at the time of death or move New HIV V+ Diagnos ses (n) HIV-1 RNA, copies/ < 500 ml ,000-49,999 50, Montaner J, et al. CROI Abstract 88LB. Reproduced with permission.
10 Evaluation of association between expansion of ART coverage, population level HIV viral load and new HIV diagnoses in British Columbia Expansion of ART access in associated with a significant decline in new HIV diagnoses After 2007, ~50% decrease in new HIV diagnoses among IDU occurred New HIV + Diagnoses (All) Active on HAART New HIV + Diagnoses (IDU) Montaner J, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 88LB.
11 Modified from Joseph Eron, MD Professor, University of North Carolina School of Medicine, Chapel Hill, NC And
12 ACTG 5202: First-line Therapy With ABC/3TC vs TDF/FTC + EFV vs ATV/RTV Stratified by HIV-1 RNA < or 100,000 copies/ml Wk 96 primary endpoint *Double blind. Open label. Antiretroviral-naive patients with HIV-1 RNA 1000 copies/ml and any CD4+ cell count (N = 1857) TDF/FTC* 300/200 mg QD +EFV 600 mg QD (n = 464) ABC/3TC* 600/300 mg QD + EFV 600 mg QD (n = 465) TDF/FTC* 300/200 QD + ATV/RTV 300/100 mg QD (n = 465) ABC/3TC* 600/300 mg QD + ATV/RTV 300/100 mg QD (n = 463) Daar E, et al. CROI Abstract 59LB.
13 bility of No Virologic Fa ailure (% %) Proba Probability of No Virologic Failure TDF-FTC (26 events) ABC-3TC (57 events) P<0.001, log-rank test Hazard ratio, 2.33 (95% CI, ) Results similar between EFV and ATV/r arms Weeks since Randomization No. at Risk ABC- 3TC TDF-FTCFTC These results were not different by EFV vs. ATV/r arm Sax PE, et al. NEJM 2009;361:
14 Similar time to virologic failure with ATV/RTV vs EFV when combined with either ABC/3TC or TDF/FTC in overall population analysis With ABC/3TC, C, HR: 1.13 (95% CI: ) With TDF/FTC, HR: 1.01 (95% CI: ) ut (%) nts Withou c Failure ( Patien Virologi ATV/RTV EFV % without VF ABC/3TC TDF/FTC Daar E, et al. CROI Abstract 59LB.
15 nt Perce ABC/3TC 6565 TDF/FTC Viral failures No baseline resistance (N) 60 Any Major Mutation 50 NNRTI Mutation P< P< NRTI Mutation P= P= PI Mutation ATV/r EFV ATV/r EFV 23 Modified from CCO P-values: ATV/r vs. EFV (among failures) * Major mutations defined by IAS-USA (2008) list plus T69D, L74I, G190C/E/Q/T/V for RT and L24I, F53L, I54V/A/T/S and G73C/S/T/A for PR Daar E, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 59LB.
16 From %) in BMD F o Wk 96 (% Mean BL to Comparison of ABC/3TC vs Comparison of EFV vs TDF/FTC ATV/RTV ABC/3TC TDF/FTC EFV ATV/RTV P =.004 P =.025 P =.035 P =.59 0 n = Difference: 2.0% Difference: 1.5% From %) in BMD F o Wk 96 (% Mean BL to n = Difference : 1.5% Difference: 0.3% Lumbar Spine Hip Lumbar Spine Hip Initial loss in BMD in all arms stabilized after Wk 48 No significant differences in fracture rates between arms McComsey G, et al. CROI Abstract 106LB.
17 Can intensification ifi ti with a new class ARV improve CD4 counts? in viral suppressed patients with HAART for >48 wks but remaining suboptimal CD4 count Adding maraviroc Adding raltegavir
18 Intensification of Stable HAART in Pts With Suboptimal CD4+ Cell Counts ACTG 5256: Maraviroc added for 24 wks in 32 pts with HIV-1 RNA < 50 copies/ml for 48 wks on stable HAART but CD4+ cell count < 250 cells/mm 3[1] Maraviroc intensification not associated with clinically significant CD4+ gain Median CD4+ count increase at Wk 22/24: +12 cells/mm 3 (90% CI: 1-22) Decrease in CD4+/CD8+ activation and improvements in markers of apoptosis, but not correlated with change in CD4+ cell count Raltegravir intensification also not associated with significant CD4+ cell count increases in suppressed pts with low CD4+ cell counts [2] 1. Wilkin TJ, et al. CROI Abstract Hatano H, et al. CROI Abstract 101LB.
19 Modified from Calvin Cohen, MD Research Director, CRI New England Harvard Vanguard Medical Associates Boston MA
20 ODIN: Study Design Phase IIIb, randomized, open-label study Treatment phase (up to 48 weeks) ARV-experienced patients, aged 18 years HIV-1 RNA >1000 copies/ml CD4 cell count >50 cells/mm 3 No DRV RAMs at screening* Stable HAART for 12 weeks DRV/r 800/100mg qd + OBT (n=294) DRV/r 600/100mg bid + OBT stratified by (n=296) screening HIV-1 RNA ( 50,000, >50,000 copies/ml) * DRV RAMs include the following mutations: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V Individualized OBT included 2 N(t)RTIs based on ARV history and resistance testing Only restrictions on previous therapy: use of enfuvirtide, tipranavir, DRV, current use of investigational drugs ARV = antiretroviral; HAART = highly-active antiretroviral therapy; OBT = optimized background therapy; qd = once-daily; bid = twice-daily; RAMs = resistance-associated mutations Cahn P, et al. 17th CROI; San Francisco, CA, US; February 16-19, Abst. 57
21 ODIN: HIV-1 RNA < 50 copies/ml at Wk 48 Overall and by Screening HIV-1 RNA Pts With HIV-1 RNA < 50 copie es/ml (%) Difference in response, QD vs BID: ITT = 1.2% (95% CI: -6.1%, 8.5%) Wks QD DRV/RTV 800/100 mg BID DRV/RTV 600/100 mg Pts With HIV-1 RNA < 50 copie es/ml (%) n = ,000 > 50,000 Screening HIV-1 RNA (copies/ml) Similar CD4+ cell count increase between arms QD DRV/RTV : +100 cells/mm 3 BID DRV/RTV : +94 cells/mm 3 Cahn P, et al. CROI Abstract 57. Reproduced with permission.
22 ODIN: Virologic Failure Not Statistically Different Between Arms Resistance Emergence in Pts QD DRV/RTV + BID DRV/RTV + With Virologic Failure and OBR OBR Paired Genotypes/Phenotypes Development of new RAMs,* n (%) Primary PI 1 (1.7) 0 Any PI 7 (11.7) 4 (9.5) Loss of susceptibility, n (%) Darunavir 1 (1.7) 0 Any PI 2 (3.4) 0 *Patients with paired baseline/endpoint genotypes evaluated (n = 60 in QD arm and n = 42 in BID arm). Patients with paired baseline/endpoint phenotypes evaluated (n = 59 in QD arm and n = 41 in BID arm). Cahn P, et al. CROI Abstract 57.
23 ODIN: Significantly Lower Rate of Lipid Abnormalities With DRV/RTV QD vs BID AEs,* % QD DRV/RTV BID DRV/RTV P Value + OBR + OBR (n = 294) (n = 296) Serious AEs Grade 2-4 treatment-related related lab abnormalities* Total cholesterol <.0007 LDL-C <.019 Ti Triglycerides id <.014 *No significant differences in grade 3/4 AEs, AEs leading to treatment discontinuation, GI AEs, ALT levels, or AST levels. Cahn P, et al. CROI Abstract 57.
24 Modified from Andrew Zolopa, MD Associate Professor, Stanford University School of Medicine Palo Alto, CA
25 % Virologic Failure *ASP detects specific mutations Sensitivity to 0.1% 41% 14% ASP+ ASP 9% 9% 32% 13% NVP LPV/r NVP Overall Baseline GT: no NNRTI R Boltz V, et al. 17th CROI; San Francisco CA USA; February 16-19, Abst. 154.
26 Report of HIV superinfection in MSM (M1 and M2) Source patient (M2) MDR HIV on partially suppressive LPV/r + ABC/3TC regimen Superinfected patient (M1) HIV RNA<50 c/ml on ABC/AZT/3TC Sudden increase in HIV RNA to >200 c/ml with further rebound Rebound associated with 3 class resistance that matched M1 Phylogenetically related viruses found in M1 and M2 M1 HIV displaced by M2 HIV Resistance mutations to ART present in M1 ( ) and M2 (2008) HIV-1 genotypic analyses RTI Mutations 41L 74I 75M 75T 98G 103N 108I 115F/Y 184V 215Y 318F 399D M1 X X X X X X N X X X X M2 X X X X X X X X X X Pl Mutations 10V 13V 20R 32I 33I 46I 47V 50V 71I 77I 82A 89V 90M 93L M1 X X X X X X X X X X N X X X M2 X X X X X X X X X X X X X Castro E, et al. 17th CROI; San Francisco CA USA; February 16-19, Abst. 480.
27 Modified from Paul Sax, MD Associate Professor, Harvard Medical School Boston, MA
28 ABC/3TC Median Change in Fasting Lipids (mg/dl) TC LDL HDL TG ATV/r EFV p-value <0.001 <0.001 < TDF/FTC ATV/r EFV p-value < < In low HIV RNA stratum, in comparison between ABC/3TC vs. TDF/FTC: significantly greater increase in TC, LDL, HDL with both EFV and ATV/r; greater increase in TG with ATV/r Daar E, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 59LB.
29 Change in Calculated Creatinine Clearance (ml/min) Week 48 Week 96 ABC/3TC ATV/r EFV p-value TDF/FTC ATV/r EFV p-value <0.001 Daar E, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 59LB.
30 TDF/FTC QD ABC/3TC Placebo QD ABC/3TC QD TDF/FTC Placebo QD Enrolled in Substudy EFV QD N=69 EFV QD N=70 EFV vs. ATV/r TDF/FTC vs. ABC/3TC EFV N=139 TDF/FTC N=139 TDF/FTC QD ABC/3TC Placebo QD ABC/3TC QD TDF/FTC Placebo QD ATV/r QD N=65 ABC/3TC N=135 ATV/r N=130 ATV/r QD N=65 Study Evaluations: - DXA at 0, 24, 48, 96 weeks, then yearly - CT abdomen at 0 and 96 weeks - Serum lipids and plasma Primary endpoints (TDF/FTC vs. ABC/3TC): 1) Percent change in hip and lumbar spine BMD 2) 10% loss of limb fat Secondary endpoints: 1) bone and fat loss between EFV and ATV/r 2) on-study fractures McComsey, G, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 106LB.
31 P=0.004 D percent eek 0 spine BMD ge from we Lumbar s chang NNRTI/PI Component Secondary Analysis P=0.035 ATV/r EFV Visit from randomization (week) * linear regression No significant interaction of NRTI and NNRTI/PI components (P=0.63) McComsey G, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 106LB.
32 Randomized, double-blind blind study comparing RAL vs EFV, both with TDF/FTC Week 96 lipids (all pts, n=563) EFV increased TC, HDL- C, LDL-C, TG, and glucose significantly more than RAL No significant difference in total/hdl chol ratio Dexa substudy (n=111) Overall, limb fat increased over time By week 96, 3/37 pts on RAL, 2/38 on EFV had >20% loss of limb fat Lipid Changes p <0.001 * P =0.025 * Mean Percent Change in Appendicular Fat DeJesus E, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 720.
33 Modified from Ian Frank, MD Professor of Medicine Director, Clinical-Therapeutics Program University of Pennsylvania Center for AIDS Research Philadelphia, PA
34
35 Methods: Time from D:A:D enrollment to first MI by time-updated TG level Adjustments for associations of independence from other CAD risks Subjects (n = 30,703): Age 39; White 54%; Current smoker 37%; CD4+ 407; HIV RNA BLQ 33% 580 MIs over 178,835 PY After adjustments for other CVD risks, doubling n = 30,703 of TG associated with an 11% increased risk for MI Incidence of MI according to TG group PY = Patient-Years Worm S, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 127.
36 N= 6,842 with 33 creatinine measurements + body weight (2004) : with 21,482 person-years of follow-up Definition of CKD (egfr by Cockcroft-Gault) If baseline egfr 60 ml/min/1.73 m 2, fall to <60 If baseline egfr <60 ml/min/1.73 m 2, fall by 25% 225 (3.3%) progressed to CKD Cumulative Exposure to ARVs and Risk of CKD ARV Multivariable IRR/year 95% CI P-value Tenofovir < Indinavir < Atazanavir Lopinavir/r Risk factors for CKD on TDF: age, HTN, HCV, lower egfr, lower CD4+ count Kirk O, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 107LB.
37 Comparison of HOPS cohort Gender-adjusted rates of fracture (n=8,456) vs National Hospital among adults aged years Discharge Survey and National Hospital Ambulatory Medical Care Survey (NHAMCS) Adjusted for age and gender HOPS: 276 Fractures during median 4.8 yrs follow-up Risk factors for fractures Age >47 Nadir CD4+ count <200 HCV co-infection Diabetes Substance use Conclusion: Fracture rates are higher in HIV infected population and rate is increasing with age HOPS P value for trend = 0.01 P value for trend = 0.32 NHAMCS- OPD Dao C, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 128.
38 Retrospective analysis of 1728 HIV+ and 663 HIV- individuals Fractures at hip, spine, wrist or other site Ever or within past 6 months Demographics (HIV+) 56% black, median age = 40, BMI = 28 Medical History (HIV+) Smoking 45%, Vitamin D supplements 42%, Menopause 20%, HCV+ 25% CD4+ count = 482 On ARVs 66%; Median years ART 5 +/- 10 No. Incident Fracture (%) HIV + HIV - Fracture/ 100 py No. Incident Fracture (%) Fracture/ 100 py P-value Any Site 148 (9%) (7%) Spine 15 (1%) (1%) Hip 15 (1%) (1%) Wrist 25 (1%) (1%) Other 105 (6%) (4%) Yin M, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 130.
39 Modified from Jürgen Rockstroh, MD Professor, University of Bonn Bonn, Germany
40 Population attributable risk among people with AIDS in the US Cumulativ ve Incide ence (%) AIDS Defining Cancer NonAIDS Defining Cancer Simard E, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 27.
41 VA-Cohort (3,707 HIVpositive patients) Predominantly male (98%), 30 white (43%) Median age 47 years Lung cancer risk factors Smoking and drug abuse more often among HIV+ Similar rates of COPD After adjustment for smoking, risk of lung cancer higher in HIV+ patients Cases per 10,000 pt y yrs cases per 10,000 pt-yrs HIV+ 15 cases per 10,000 pt-yrs HIV IRR for lung 1.5 (95% CI: ) Sigel K, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 30.
42 Modified from Edwin DeJesus, MD, FACP Medical Director, Orlando Immunology Center Orlando, FL
43 urban poor population In comparison to other commonly prescribed regimens, EFV/TDF/FTC exhibited higher rates of adherence and virologic suppression Virological i l suppression was better with EFV/TDF/FTC even when comparing patients with lower adherences rates Bangsberg D, et al. 17th CROI; San Francisco, CA; February 16 19, Abst. 510.
44
45 New CCR5-inhibitor Vicriviroc (Merck ) Phase III Results
46 Wk 48 Treatmentexperienced patients infected with CCR5-tropic HIV-1 only (N = 721*) Vicriviroc 30 mg QD + OBR (VICTOR-E3: n = 252; VICTOR-E4: n = 234) Placebo + OBR (VICTOR-E3: n = 123; VICTOR-E4: n = 112) *Modified ITT population includes patients with CCR5-only tropism at baseline, confirmed retrospectively using enhanced sensitivity phenotypic tropism assay. OBR selected by investigator: must contain 2 fully active drugs; must include ritonavir-boosted PI; etravirine only permitted NNRTI; raltegravir and darunavir permitted. Gathe J, et al. CROI Abstract 54LB.
47 % with viral loa ad <50 c/ml Vicriviroc Placebo 70* *p= CD4+ count increased 138±7.33 with vicriviroc vs 29 ± 9.4 cells/mm 3 with placebo 0 Overall OSS 3 OSS 2 OSS = overall N= 486; 235 N= 293; 65 N= 176; 85 Gathe J, et al. CROI Abstract 54LB. sensitivity score
48 Lack of incremental benefit from vicriviroc i i may reflect high underlying activity of OBR Pts, % Vicriviroc Phase III [1] Maraviroc Phase III [2] Raltegravir Phase III [3] PSS = 0 < PSS = PSS = PSS = Gathe J, et al. CROI Abstract 54LB. 2. Fätkenheuer G, et al. N Engl J Med. 2008;359: Steigbigel RT, et al. N Engl J Med. 2008;359:
49 But will investigate as first-line Rx
50 Treatment-naïve HIV RNA 5,000 copies/ml CD4 cells >50 cells/mm 3 No Resistance to NRTIs NNRTIs PIs HBV- and HCV-negative 2:1 2:1 EVG/GS-9350/TDF/FTC + placebo n=48 EFV/TDF/FTC + placebo n=23 GS placebo ATV + FTC/TDF n=50 RTV + placebo ATV + FTC/TDF n=29 Randomization stratified by HIV RNA ( or >100,000 copies/ml) Primary Endpoint: Proportions with HIV RNA <50 copies/ml at Week week trials Cohen C, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 58LB.
51 with pies/ml ercentage w NA <50 cop Pe HIV RN EVG/GS-9350 vs. EFV Week 24 stratum-weighted difference +5% (95% CI: -11.0% to 21.1%) Week 90% 83% EVG/GS-9350/TDF/FTC EFV/FTC/TDF with pies/ml ercentage w RNA <50 co P HIV R RTV vs. GS-9350 Week 24 stratum-weighted difference -1.9% (95% CI: -18.4% to 14.7%) Week 86% 84% RTV + ATV + TDF/FTC GS ATV + TDF/FTC Cohen C, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 58LB.
52 under development by Tobira Potent Oral CCR5 and CCR2 receptor antagonist In vitro protein-adjusted EC50=0.29 nm for R5 Neither a CYP inducer nor inhibitor Additive / synergistic activity with other ART classes in vitro Oral bioavailability y( (current formulation) enhanced by food Once daily dosing (Plasma T ½=35-40 hours) Study Design: Ten day monotherapy, R5-tropic pts CCR2 receptors are associated with, and currently being studied in several inflammation-associated associated diseases (atherosclerosis, rheumatoid arthritis, insulin resistance) Thus far no significant safety signals are identified with CCR2 antagonists Cohen C, et al. 17th CROI; San Francisco CA USA; February 16-19, Abst. 53
53 Median VL Response Nadir Viral load Response 10 day dosing Note: CCR2 inhibition observed using MCP-1 level increases Cohen C, et al. 17th CROI; San Francisco CA USA; February 16-19, Abst. 53
54 TBR-652: Summary of Adverse Events TBR-652 Dose Cohort Placebo 25 mg (n=9) 50 mg (n=7) 75 mg (n=9) 100 mg (n=10) 150 mg (n=9) (n=10) Any SAE Any AE Diarrhea Abdominal discomfort Fatigue Nausea Pyrexia Headache * AEs in 2 patients or more per cohort judged at least possibly related to study drug. Cohen C, et al. 17th CROI; San Francisco CA USA; February 16-19, Abst. 53
BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 COMPLICATIONS OF HIV DISEASE AND TREATMENT Overview Cardiovascular
More informationThe 17th Conference on Retroviruses and Opportunistic Infections* ARV Therapies and Therapeutic Strategies A CME Newsletter
* CROI 2010 * February 16-19, 2010 San Francisco, CA Course Director Calvin Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts Faculty Jürgen
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationThe BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir
The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects with Virologic Suppression
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationKiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre
Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre www.iasusa.org; www.aidsinfo.nih.gov; www.clinicaloptions.com; www.clinicaloptions.com/hiv
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationPrevalence of Comorbidities among HIV-positive patients in Taiwan
Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationHIV: Approach to the Treatment-Naïve Patient
HIV: Approach to the Treatment-Naïve Patient Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Approach
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationChronic complications of HIV infection. An update Pablo Tebas, MD
Activity Code TM809 Chronic complications of HIV infection. An update 2014 Pablo Tebas, MD Learning Objectives Upon completion of this presentation, learners should be better able to: Identify and update
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationD:A:D: Cumulative Exposure to DRV/r Increase MI Risk
D:A:D: Cumulative Exposure to DRV/r Increase MI Risk 20.0-15.0-10.0-5.0-4.0-3.0-2.0-1.0- Unadjusted CVD rate ratios per 5 years additional exposure: ATV/r 1.25 [1.10-1.43] and DRV/r 1.93 [1.63-2.28] Adjusted*
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationProfessor José Arribas
19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationHIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD
HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationAdvances in HIV Treatment: When to Start Treatment Which Antivirals to Use
Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use Calvin Cohen MD Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston MA Learning
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationHIV10 November 7-11, 2010 Glasgow, Scotland
HIV1 November 7-11, 21 Glasgow, Scotland Course Director Calvin Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts Faculty José Arribas,
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationPerspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI)
Perspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI) Gianni Di Perri Dept. de Maladies Infectieuses Universitè de Turin Ospedale Amedeo di Savoia Fusion inhibitors
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationHIV Prevention. David Cooper, MD, DSc Director and Professor, Kirby Institute University of New South Wales Sydney, Australia
HIV Prevention David Cooper, MD, DSc Director and Professor, Kirby Institute University of New South Wales Sydney, Australia HIV Care/Prevention Continuum Test Engage, Counsel, Monitor and Support Retain,
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationWhen to Start HIV Treatment? Which Treatments to Start?
When to Start HIV Treatment? Which Treatments to Start? Calvin Cohen MD Harvard Medical School Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston USA
More information16th Conference on Retroviruses and Opportunistic Infections ARV Therapies and Therapeutic Strategies A CME Newsletter
CROI 2009 8-11, February 2009 Montréal, Canada Course Director John Bartlett, MD Professor of Medicine Johns Hopkins University Baltimore, MD Faculty Rafael Campo, MD Professor of Clinical Medicine University
More informationBHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes
BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy START & other changes Contents Introduction & treatment aims Major changes When to start What to start BHIVA: what
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationHIGH VIRAL LOAD AND TREATMENT RESPONSE
16 th Annual Resistance and Antiviral Dr Bonaventura Clotet Hospital Germans Trias i Pujol, Barcelona, Spain Thursday 20 September 2012, Wellcome Collection Conference Centre, London HIGH VIRAL LOAD AND
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More information